anpc - ANPC STOCK NEWS

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) announced the granting of its first disease treatment patent on June 7, 2021, covering novel medical devices for cancer detection and treatment with 25 claims. This is the company's 21st patent issued in the U.S. Additionally, AnPac's newly launched joint venture has secured over $4 million in funding for cancer treatment device fabrication and testing. The CEO emphasized the synergy between their cancer screening and treatment initiatives, reinforcing AnPac's commitment to technological innovation and an expanding intellectual property portfolio.

AnPac Bio reported significant growth in its Q1 2021 financial results, with total revenue reaching RMB2.2 million (US$0.3 million), up 137.2% year-over-year. The gross profit margin improved to 58.4%, a rise of 25.7% compared to Q1 2020. Despite progress, the company faced a net loss of RMB29.3 million (US$4.5 million), increasing from RMB21.2 million in the previous year. Key developments include the introduction of the new CDA Pro Sensor and the approval for registration testing of a class III lung cancer diagnostic device by the NMPA. AnPac Bio is optimistic about future growth.

AnPac Bio-Medical Science Co., Ltd. (ANPC) announced the formation of a joint venture to develop new cancer treatment technology in partnership with Dr. Chris Chang Yu and others. AnPac will contribute two patent applications for assessment and ownership distribution based on their appraised value. The technology builds on findings from over 222,200 samples related to early-stage cancer detection. Laboratory tests are expected to commence in Q3 2021, with plans for a Class III medical device registration in China targeted for Q3 2022.

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) has filed its annual report on Form 20-F for the fiscal year ending December 31, 2020, with the SEC as of April 30, 2021. The report includes audited consolidated financial statements and is accessible on the SEC's website and the company's investor relations page. AnPac Bio specializes in early cancer screening and detection, holding 142 patents as of March 31, 2021. The company's Cancer Differentiation Analysis technology can detect over 20 cancer types with high sensitivity and specificity.

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) reported strong financial results for fiscal year 2020, with total revenues rising 89.1% to RMB20.5 million (US$3.1 million), driven by increased demand for cancer screening tests. Gross margin improved to 62.8%, up from 44.2% in 2019. The net loss decreased to RMB80.6 million (US$12.3 million), a reduction of 20.7% from the previous year. The company launched two new products and received CAP certification for its San Jose lab, enhancing its market position. AnPac Bio remains focused on R&D and expanding its product offerings.

AnPac Bio-Medical Science Company (NASDAQ: ANPC) will release its fiscal year 2020 unaudited financial results on April 30, 2021, before the U.S. market opens. An earnings call is scheduled for the same day at 8:30 am ET. The company specializes in early cancer screening and detection and has 142 issued patents as of March 31, 2021. AnPac was ranked third globally in next-generation cancer screening technologies by Frost & Sullivan, having processed approximately 41,700 clinical samples as of December 31, 2019.

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) reported record growth in its paid cancer differentiation analysis (CDA) tests during Q1 2021, achieving a 130% increase with 5,439 tests performed. This surge, occurring despite the typical seasonal slowdown, indicates strong market demand and acceptance of the company's innovative multi-cancer screening technology. AnPac aims to leverage this growth in both Chinese and U.S. markets, where it holds 142 patents and operates multiple certified laboratories, further enhancing its position in the rapidly growing cancer screening sector.

AnPac Bio-Medical Science Co., Ltd. (ANPC) announced the development of a new multi-cancer detection sensor, the CDA Pro Sensor (CDAPS), with enhanced capabilities compared to previous models. Key improvements include a cost reduction of approximately 137% and detection sensitivity and specificity exceeding 95%. This advancement in cancer detection signals aims to improve early cancer screening, addressing long-standing challenges in obtaining stable and high-quality detection signals. AnPac Bio’s experience and patent portfolio support its competitive edge in the biotechnology sector.

AnPac Bio-Medical Science Co., Ltd. (ANPC) announced it has regained compliance with the Nasdaq Listing Rule after its market value surpassed $50 million for 12 consecutive business days from February 16 to March 3, 2021. This compliance follows prior notification from Nasdaq regarding non-compliance due to a market value drop below the required threshold. CEO Dr. Chris Yu expressed satisfaction in regaining compliance, emphasizing its importance for accessing capital markets and enhancing shareholder liquidity. AnPac Bio focuses on early cancer detection technologies with 128 issued patents.